docetaxel anhydrous has been researched along with Multiple Myeloma in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Turki, T; Wang, JTL; Wei, Z | 1 |
| Bandapalli, OR; Campo, C; da Silva Filho, MI; Försti, A; Goldschmidt, H; Hemminki, K; Mahmoudpour, SH; Merz, M | 1 |
| Che, Y; Hou, S; Kang, Z; Lin, Q | 1 |
| Liu, BL; Liu, X; Qi, MY; Xu, B; Zhou, NC | 1 |
| Blood, E; Friedenberg, WR; Graham, D; Greipp, P; Winston, RD | 1 |
| Alsina, M; Beam, C; Beaupre, DM; Dalton, W; Gerbino, E; Hamilton, AD; Kerr, WG; Lichtenheld, MG; Mackley, PA; Muro-Cacho, C; Sebti, SM; Zhu, K | 1 |
| Alexandre, J | 1 |
| Avcu, F; Ural, AU | 1 |
| Karatapanis, S; Marinopoulos, S; Rasidakis, A; Skorda, L | 1 |
| Lyerly, HK; Morse, MA; Vredenburgh, JJ | 1 |
1 trial(s) available for docetaxel anhydrous and Multiple Myeloma
| Article | Year |
|---|---|
The treatment of multiple myeloma with docetaxel (an ECOG study).
Topics: Adult; Aged; Agranulocytosis; Antineoplastic Agents, Phytogenic; Docetaxel; Female; Humans; Male; Middle Aged; Multiple Myeloma; Paclitaxel; Salvage Therapy; Survival Analysis; Survival Rate; Taxoids; Thrombocytopenia; Treatment Failure | 2003 |
9 other study(ies) available for docetaxel anhydrous and Multiple Myeloma
| Article | Year |
|---|---|
A transfer learning approach via procrustes analysis and mean shift for cancer drug sensitivity prediction.
Topics: Algorithms; Antineoplastic Agents; Area Under Curve; Bortezomib; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cisplatin; Clinical Trials as Topic; Computational Biology; Databases, Factual; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Machine Learning; Multiple Myeloma; Triple Negative Breast Neoplasms | 2018 |
Chemotherapy-induced peripheral neuropathy: evidence from genome-wide association studies and replication within multiple myeloma patients.
Topics: Aged; Bortezomib; Docetaxel; Drug-Related Side Effects and Adverse Reactions; Female; Genome-Wide Association Study; Humans; Male; Middle Aged; Multiple Myeloma; Nervous System; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Peripheral Nervous System Diseases; Polymorphism, Single Nucleotide; Risk Factors; Taxoids; Vincristine | 2018 |
Serenoa repens induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of STAT 3 signaling.
Topics: Apoptosis; Cell Line, Tumor; Cell Proliferation; Cyclin-Dependent Kinase Inhibitor p27; Docetaxel; Extracellular Signal-Regulated MAP Kinases; Humans; Interleukin-6; Intracellular Signaling Peptides and Proteins; Multiple Myeloma; Phosphorylation; Phytotherapy; Serenoa; Signal Transduction; STAT3 Transcription Factor; Taxoids; Tyrphostins | 2009 |
[Effects of docetaxel on proliferation and apoptosis of human multiple myeloma cell RPMI8226].
Topics: Apoptosis; Caspase 3; Caspase 8; Cell Line, Tumor; Cell Proliferation; Docetaxel; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Taxoids | 2012 |
Farnesyltransferase inhibitor R115777 (Zarnestra, Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Blotting, Western; Bone Marrow Cells; Caspase 3; Caspases; Cell Cycle; Cell Division; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clinical Trials as Topic; Cytochromes c; Deoxycytidine; Docetaxel; Dose-Response Relationship, Drug; Doxorubicin; Drug Synergism; Enzyme Activation; Farnesyltranstransferase; Flow Cytometry; Fluorouracil; G2 Phase; Gemcitabine; Homozygote; Humans; In Situ Nick-End Labeling; Inhibitory Concentration 50; Mice; Mice, SCID; Mitosis; Multiple Myeloma; Paclitaxel; Quinolones; Taxoids; Tetrazolium Salts; Thiazoles | 2005 |
[Proteasome inhibitors].
Topics: Adenocarcinoma; Animals; Anti-Inflammatory Agents; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dexamethasone; Docetaxel; Drug Therapy, Combination; Female; Graft vs Host Reaction; Humans; Kidney Neoplasms; Lung Neoplasms; Lymphoma, Mantle-Cell; Male; Mice; Multiple Myeloma; Prostatic Neoplasms; Protease Inhibitors; Proteasome Inhibitors; Pyrazines; Taxoids; Time Factors; Treatment Outcome; Tumor Cells, Cultured | 2005 |
Additive/synergistic anti-tumoral effects of the combination of docetaxel and zoledronic acid on prostate cancer cells: possible mechanisms?
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Cycle; Cell Line, Tumor; Diphosphonates; Docetaxel; Drug Synergism; Humans; Imidazoles; Male; Multiple Myeloma; Prostatic Neoplasms; Taxoids; Zoledronic Acid | 2006 |
Multiple myeloma emerging after chemotherapy for non-small-cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplatin; Docetaxel; Humans; Lung Neoplasms; Male; Multiple Myeloma; Neoplasms, Second Primary; Taxoids; Topotecan; Vinblastine; Vinorelbine | 2008 |
A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cells, Cultured; Culture Media, Serum-Free; Cyclophosphamide; Dendritic Cells; Docetaxel; Female; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Interleukin-4; Leukapheresis; Leukocyte Count; Lymphocyte Culture Test, Mixed; Lymphoma, Non-Hodgkin; Multiple Myeloma; Neutropenia; Paclitaxel; Taxoids | 1999 |